CYTODYN GETS GREENLIGHT FROM ITS INVESTIGATORS FOR CHINA JOINT VENTURE AND GLAXO WINS ROTAVIRUS VACCINE APPROVAL IN EUROPE

CytoDyn, Inc. has been advised by its investigators in the United States and Hong Kong that there is no derogatory information that would preclude the Company from joining with Timeway International for a joint venture in China. The anticipated joint venture would develop Cytolin, CytoDyn's targeted immune therapy for HIV/AIDS, in that populous Asian nation.

Financial News USA (http://www.financialnewsusa.com/release.php?rlsid=4367)